FibroBiologics, Inc.

FBLG

US31573L1052

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-28 pm EDT			5-day change	1st Jan Change
11.99 ^USD	+4.44%		+9.00%	0.00%

May. 14	FibroBiologics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 25	FibroBiologics, Inc. Plans to Collaborate with Charles River Laboratories to Manufacture Fibroblast-Based Spheroids	CI

FibroBiologics, Inc.(NasdaqGM:FBLG) added to NASDAQ Composite Index

February 01, 2024 at 12:00 am EST

FibroBiologics, Inc. has been added to Nasdaq Composite Index .

Latest news about FibroBiologics, Inc.

FibroBiologics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 14	CI
FibroBiologics, Inc. Plans to Collaborate with Charles River Laboratories to Manufacture Fibroblast-Based Spheroids	Apr. 25	CI
Fibrobiologics Presents Data from Dermal Fibroblast Spheroid-Based Treatment of Chronic Wounds in A Diabetes Mouse Model At Advanced Wound Care Summit USA	Apr. 04	CI
Wall Street Set to Open Flat as Investors Look Toward Fed Decision; Oil Prices Drop Sharply	Mar. 20	MT
FibroBiologics, Inc. Appoints Ruben A. Garcia as General Counsel	Mar. 06	CI
FibroBiologics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29	CI
Top Premarket Gainers	Feb. 28	MT
FibroBiologics, Inc. to Present Preclinical and Clinical Data at the 2024 Americas Committee for Treatment and Research in Multiple Sclerosis Forum	Feb. 20	CI
FibroBiologics Presents Preclinical Data at the 2024 Keystone Symposia for Systemic Autoimmune and Autoinflammatory Diseases	Feb. 13	CI
Top Premarket Gainers	Feb. 01	MT
FibroBiologics, Inc.(NasdaqGM:FBLG) added to NASDAQ Composite Index	Feb. 01	CI

FibroBiologics Inc is a United States-based company. The Company operates as a biopharmaceutical company. It is focused on developing and commercializing fibroblast cell-based therapies for patients suffering from chronic diseases. It also develops biologic cures and treatments for chronic diseases, including degenerative disc disease, multiple sclerosis, wound healing, and cancer, and anti-aging extension of life applications such as thymic involution reversal and splenic involution reversal.

Sector

Biotechnology & Medical Research

Calendar

2024-06-04 - Bio International Convention

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
FIBROBIOLOGICS, INC.	0.00%	373M
VERTEX PHARMACEUTICALS INCORPORATED	+9.83%	118B
REGENERON PHARMACEUTICALS, INC.	+10.80%	106B
BIONTECH SE	-10.84%	23.4B
ARGENX SE	-1.69%	22.1B
GENMAB A/S	-10.23%	18.34B
WUXI APPTEC CO., LTD.	-41.92%	16.59B
BEIGENE, LTD.	-15.11%	15.97B
NEUROCRINE BIOSCIENCES, INC.	+6.62%	14.03B
SAREPTA THERAPEUTICS, INC.	+17.53%	11.67B